Pirfenidone in Patients With Unclassifiable Progressive Fibrosing Interstitial Lung Disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Pirfenidone in Patients With Unclassifiable Progressive Fibrosing Interstitial Lung Disease: A Double-Blind, Randomised, Placebo-Controlled, Phase 2 Trial
Lancet Respir Med 2019 Sep 27;[EPub Ahead of Print], TM Maher, TJ Corte, A Fischer, M Kreuter, DJ Lederer, M Molina-Molina, J Axmann, KU Kirchgaessler, K Samara, F Gilberg, V CottinFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.